We are live on ! Find out more
AMLX icon

Amylyx Pharmaceuticals
AMLX

171 hedge funds and large institutions have $1.59B invested in Amylyx Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 62 increasing their positions, 53 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

503% more call options, than puts

Call options by funds: $9.02M | Put options by funds: $1.5M

17% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 53

17% more capital invested

Capital invested by funds: $1.36B → $1.59B (+$230M)

1.02% more ownership

Funds ownership: 102.24% → 103.27% (+1%)

4% less funds holding

Funds holding: 179 → 171 (-8)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

19% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 36

Holders
171
Holders Change
-8
Holders Change %
-4.47%
% of All Funds
2.1%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.06%
New
29
Increased
62
Reduced
53
Closed
36
Calls
$9.02M
Puts
$1.5M
Net Calls
+$7.52M
Net Calls Change
+$2.34M

Top Buyers

1
SL
Siren LLC
Connecticut
+$17.3M
2
Franklin Resources
Franklin Resources
California
+$14.9M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$11M
4
Barclays
Barclays
United Kingdom
+$9.52M
5
JAM
Jupiter Asset Management
United Kingdom
+$8.12M

Top Sellers

1
SI
Sofinnova Investments
California
-$6.37M
2
SCM
Silverarc Capital Management
Massachusetts
-$6.12M
3
Ameriprise
Ameriprise
Minnesota
-$6.07M
4
PSC
Patient Square Capital
California
-$4.23M
5
NCM
Nantahala Capital Management
Connecticut
-$4.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$231M +$1.58M +112,122 +0.7%
BlackRock
2
BlackRock
New York
$123M -$3.17M -225,595 -2%
PA
3
Perceptive Advisors
New York
$115M – – –
TCM
4
TCG Crossover Management
California
$86.8M – – –
CC
5
Commodore Capital
New York
$78.5M – – –
Janus Henderson Group
6
Janus Henderson Group
United Kingdom
$69.3M +$7.32M +520,201 +12%
SVCM
7
Saturn V Capital Management
Texas
$60.5M -$2.06M -146,602 -3%
VCM
8
Vanguard Capital Management
Pennsylvania
$57.6M +$58.3M +4,141,575 New
Adage Capital Partners
9
Adage Capital Partners
Massachusetts
$49.5M +$11M +783,709 +28%
FLAM
10
First Light Asset Management
Minnesota
$44.3M -$2.32M -164,894 -5%
DCM
11
Driehaus Capital Management
Illinois
$41.5M -$1.72M -122,356 -4%
Goldman Sachs
12
Goldman Sachs
New York
$36.5M +$180K +12,770 +0.5%
State Street
13
State Street
Massachusetts
$32.8M +$4.13M +293,277 +14%
Franklin Resources
14
Franklin Resources
California
$31.4M +$14.9M +1,061,473 +88%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$30.7M +$639K +45,398 +2%
Morgan Stanley
16
Morgan Stanley
New York
$30.2M -$2.59M -184,277 -8%
AC
17
Almitas Capital
California
$29.5M – – –
GPP
18
Great Point Partners
Connecticut
$24.3M – – –
JHC
19
Jones Hill Capital
New York
$22.2M +$22.5M +1,598,794 New
6CM
20
683 Capital Management
New York
$21.3M -$1.69M -120,000 -7%
EAM
21
Eventide Asset Management
Massachusetts
$21M +$11.4K +810 +0.1%
Bank of America
22
Bank of America
North Carolina
$18.5M -$74.8K -5,321 -0.4%
Deutsche Bank
23
Deutsche Bank
Germany
$17.6M -$921K -65,451 -5%
SL
24
Siren LLC
Connecticut
$17.1M +$17.3M +1,230,000 New
Balyasny Asset Management
25
Balyasny Asset Management
Illinois
$15.4M +$3.5M +248,587 +29%
1
2 3 4 5

AMLX Hedge Fund Activity: Q1 2026 in Review

171 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q1 2026, worth a combined $1.59B — up 17% from $1.36B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of AMLX and 29 opened new positions — a net loss of 7 holders — while 53 trimmed existing stakes and 62 added.

The largest buyer was Siren LLC, opening a new position worth an estimated $17.3M. The largest seller was Sofinnova Investments, exiting entirely with an estimated $6.37M sold.

  • 171 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q1 2026, down from 179 in Q4 2025.
  • Funds reported $1.59B of Amylyx Pharmaceuticals stock for Q1 2026, up 17% quarter-over-quarter.
  • 29 funds opened new Amylyx Pharmaceuticals positions in Q1 2026 and 36 closed out, a net change of -7 holders.
  • The largest Amylyx Pharmaceuticals buyer in Q1 2026 was Siren LLC, an estimated $17.3M added.
  • The largest Amylyx Pharmaceuticals seller in Q1 2026 was Sofinnova Investments, an estimated $6.37M sold.

Based on aggregated 13F filings for Q1 2026.